Translational Research Cancer Centers Consortium Annual Meeting

转化研究癌症中心联盟年会

• 批准号: 8319055
• 负责人: Gregory B. Lesinski
• 金额: $ 0.6万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-01 至 2013-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8319055
• 关键词: Abramson Cancer Center at the University of Pennsylvania; Advertising; Advocate; Anniversary; Appalachian Region; Applications Grants; Area; Automobile Driving; Barbara Ann Karmano Cancer Institute; Biological Response Modifier Therapy; Buffaloes; Cancer Center; Caring; Climate; Clinical; Clinical Research; Clinical Trials; Coal Mining; Collaborations; Communication; Communities; Comprehensive Cancer Center; Data; Development; Education; Fostering; Foundations; Funding; Geographic Locations; Goals; Health Personnel; Health Professional; Hour; Immune system; Immunologics; Immunology; Improve Access; Incidence; Individual; Institutes; Institution; Intention; Internet; Joints; Knowledge; Laboratory Research; Location; Malignant Neoplasms; Michigan; New York; Ohio; Patient Agents; Patients; Pennsylvania; Phase; Physicians; Postdoctoral Fellow; Principal Investigator; Provider; Regional Cancer; Research; Research Personnel; Resort; Roswell Park Cancer Institute; Rural Population; Scientist; Secure; Site; Steel; Students; Therapeutic; Therapeutic Agents; Translating; Translational Research; Uncertainty; Underserved Population; United States; Universities; University of Pittsburgh Cancer Institute; Urban Population; West Virginia; base; cancer immunotherapy; career development; cost; experience; fighting; meetings; member; novel; novel therapeutics; success; symposium

DESCRIPTION (provided by applicant): We are requesting funds to provide partial meeting support for the annual meetings of the "Translational Regional Cancer Center Consortium" or TrC3. The TrC3 is a cancer immunotherapy network, established to promote biologic therapeutics in the Midwestern and Northeastern regions of the United States. For the past 14 years, laboratory and clinical researches from several of this region's cancer centers have met annually in order to exchange information about the research and new clinical trials underway at their respective cancer centers. These centers include: Abramson Cancer Center at the University of Pennsylvania, Barbara Ann Karmanos Cancer Institute at Wayne State University; Case Comprehensive Cancer Center; Mary Babb Randolph Cancer Center at West Virginia University; The Ohio State University Comprehensive Cancer Center; Penn State Cancer Institute; Roswell Park Cancer Institute; University of Pittsburgh Cancer Institute. These cancer centers are well within a couple of hours to a half day driving distance from one another. Therefore, this meeting provides benefit to researchers, physicians, other care providers and their patients in the areas bounded by these groups. Because biologic and immunologic therapy is gaining momentum, this meeting represents an important, accessible, affordable opportunity to obtain information regarding new therapeutic agents, scientific discoveries and clinical trials. This meeting has become a unique experience for various trainees in academic research including students, post-doctoral fellows, residents and other medical personnel to attend a formal scientific meeting, present data and network with experts in the field to establish professional relationships that will aid career development. These annual meetings are held the third week of February at The Seven Springs Resort in Seven Springs, PA. This central meeting site is within a reasonable driving distance from most member institutions. NCI funds will be essential for facilitating early planning, securing our conference facility, CME credit, effective advertising and maintaining an affordable registration rate to allow for trainees and underserved populations an opportunity to attend this meeting. This is especially important due to the uncertainty of institutional and corporate donations in the current financial climate. Securing NCI funds will help us to achieve the following goals of the TrC3: 1) To provide an educational opportunity for researchers and health professionals in the community on data pertinent to the biologic therapy of cancer; 2) To strengthen collaborative research and clinical trials across member institutions that will benefit patients within this geographic region. This effort will be ld by a group of investigators from the consortium including the Principal Investigator: Dr. Gregory Lesinski (Ohio State), and Co-Investigators: Dr. Elizabeth Repasky (RPCI), Dr. Pawel Kalinski (UPMC). Each of these individuals has served as a Course Director for the TrC3 meeting, when it was held at each respective institution. These investigators communicate regularly with and receive guidance from a group of co-organizers from all member cancer centers. PUBLIC HEALTH RELEVANCE: The concept of using the immune system or other biologic therapies to fight cancer is gaining tremendous momentum. This meeting will provide an affordable opportunity for various investigators and trainees from the region to come together to receive vital education on the most recent developments in this field. Furthermore, it will allow for the opportunity to develop joint clinical trials using new promising biologic agents that will e available to patients in geographic regions with a traditionally high incidence of cancer.

描述（由申请人提供）：我们正在申请资金，为“转化区域癌症中心联盟”或 TrC3 的年度会议提供部分会议支持。 TrC3 是一个癌症免疫治疗网络，旨在促进美国中西部和东北部地区的生物治疗。在过去的 14 年中，该地区多个癌症中心的实验室和临床研究每年都会举行会议，以交流有关各自癌症中心正在进行的研究和新临床试验的信息。这些中心包括：宾夕法尼亚大学艾布拉姆森癌症中心、韦恩州立大学芭芭拉·安·卡马诺斯癌症研究所；凯斯综合癌症中心；西弗吉尼亚大学玛丽·巴布·伦道夫癌症中心；俄亥俄州立大学综合癌症中心；宾夕法尼亚州立大学癌症研究所；罗斯威尔帕克癌症研究所；匹兹堡大学癌症研究所。这些癌症中心彼此之间相距不到几个小时到半天的车程。因此，这次会议为这些群体范围内的研究人员、医生、其他护理提供者及其患者带来了好处。由于生物和免疫治疗正在蓬勃发展，本次会议提供了一个重要的、容易获得的、负担得起的机会来获取有关新治疗药物、科学发现和临床试验的信息。 这次会议已成为各种学术研究学员（包括学生、博士后研究员、住院医生和其他医务人员）的独特经历，他们可以参加正式的科学会议，展示数据并与该领域的专家建立联系，建立有助于职业生涯的专业关系发展。这些年会于二月第三周在宾夕法尼亚州七泉市的七泉度假村举行。该中心会议地点距大多数成员机构均在合理的车程范围内。 NCI 资金对于促进早期规划、确保我们的会议设施、CME 信用、有效的广告和维持负担得起的注册率至关重要，以使受训者和服务不足的人群有机会参加本次会议。由于当前金融环境下机构和企业捐赠的不确定性，这一点尤其重要。保护 NCI 的安全 资金将帮助我们实现 TrC3 的以下目标： 1) 为社区研究人员和卫生专业人员提供有关癌症生物治疗相关数据的教育机会； 2) 加强成员机构之间的合作研究和临床试验，使该地理区域内的患者受益。这项工作将由该联盟的一组研究人员负责，包括首席研究员 Gregory Lesinski 博士（俄亥俄州立大学）和联合研究员：Elizabeth Repasky 博士（RPCI）、Pawel Kalinski 博士（UPMC）。当 TrC3 会议在各个机构举行时，这些人中的每一位都担任过课程总监。这些研究人员定期与所有成员癌症中心的一组共同组织者沟通并接受他们的指导。 公共卫生相关性：利用免疫系统或其他生物疗法来对抗癌症的概念正在获得巨大的发展势头。这次会议将为来自该地区的各种研究人员和学员提供一个负担得起的机会，让他们齐聚一堂，接受有关该领域最新发展的重要教育。此外，它将提供使用新的有前景的生物制剂开展联合临床试验的机会，这些生物制剂将可供传统上癌症发病率高的地理区域的患者使用。